---
document_datetime: 2024-10-01 16:52:30
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cresemba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: cresemba-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.5978968
conversion_datetime: 2025-12-24 02:51:09.455624
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cresemba

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                        |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0042/G             | This was an application for a group of variations. Extension application to add a new strength of 40 hard capsule to be used in paediatric patients 6 years and older grouped with a type II variation (C.I.6.a) in order to extend the indication to include | 27/06/2024                          | 22/08/2024                                  | SmPC, Labelling and PL           | Extension application to add a new strength of 40 mg hard capsule to be used in paediatric patients 6 years and older grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of paediatric patients aged 1 year and older for Cresemba 200 mg powder, based on final results from studies 9766-CL-0107 and 9766-CL- |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | treatment of paediatric patients aged 1 year and older for Cresemba 200 mg powder, based on final results from studies 9766-CL-0107 and 9766-CL- 0046. Study 9766-CL-0046 is a Phase 1, open-label, multicenter study to evaluate the PK, safety and tolerability of intravenous and oral isavuconazonium sulfate in paediatric patients. This study was conducted in two sequential parts: Part 1 with three intravenous dosing cohorts, and Part 2 with two oral dosing cohorts. Study 9766-CL-0107 is a Phase 2, open-label, non-comparative, multicenter study to evaluate the safety and tolerability, efficacy, and PK of isavuconazole for the treatment of invasive aspergillosis or mucormycosis in paediatric patients aged 1 to < 18 years. As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3, 6.1, 6.5 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. A revised RMP version 10 has been approved. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one Annex I_2.(c) Change or addition of a new   |            |            |      | 0046. Study 9766-CL-0046 is a Phase 1, open-label, multicenter study to evaluate the PK, safety and tolerability of intravenous and oral isavuconazonium sulfate in paediatric patients. This study was conducted in two sequential parts: Part 1 with three intravenous dosing cohorts, and Part 2 with two oral dosing cohorts. Study 9766-CL-0107 is a Phase 2, open-label, non-comparative, multicenter study to evaluate the safety and tolerability, efficacy, and PK of isavuconazole for the treatment of invasive aspergillosis or mucormycosis in paediatric patients aged 1 to < 18 years. As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3, 6.1, 6.5 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. A revised RMP version 10 has been approved.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0046 | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/07/2024 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0045 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/04/2024 | 22/08/2024 | SmPC | Table 1 (Interactions), in section 4.5 of the Cresemba SmPC was amended to improve the guidance for health care professionals in relation to the co-administration of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     | cyclophosphamide and isavuconazole. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------|
| IB/0044   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/01/2024 | n/a |                                                                                                                     |
| IA/0043   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/10/2023 | n/a |                                                                                                                     |
| IB/0041/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.z - Change in the manufacturer of AS or of a | 03/04/2023 | n/a |                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate for AS - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                 |            |            |                       |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0040/G           | This was an application for a group of variations. B.II.a.z - Change in description and composition of the Finished Product - Other variation B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.6 - Administrative change - Change in ATC | 19/12/2022 | 12/01/2024 | SmPC, Annex II and PL |                                                                                                                                            |
| IA/0039             | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                                                                                                                  | 19/09/2022 | n/a        |                       |                                                                                                                                            |
| PSUSA/10426 /202109 | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                                                                                                      | 22/04/2022 | 21/06/2022 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10426/202109. |
| IB/0038             | B.I.b.2.e - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                                                                                                   | 07/01/2022 | n/a        |                       |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                  |            |            |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0036             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                              | 28/10/2021 | 19/05/2022 | SmPC and PL            |                                   |
| II/0035/G           | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 08/07/2021 | n/a        |                        |                                   |
| IB/0034             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                   | 11/06/2021 | n/a        |                        |                                   |
| II/0030             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                              | 22/04/2021 | 19/05/2022 | SmPC, Labelling and PL |                                   |
| PSUSA/10426 /202009 | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                    | 09/04/2021 | n/a        |                        | PRAC Recommendation - maintenance |
| II/0031             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                              | 28/01/2021 | 19/05/2022 | SmPC and PL            |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0032/G           | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size   | 11/09/2020   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0027              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/05/2020   | 13/08/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Cresemba in the approved indications remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10426 /201909 | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/04/2020   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| IB/0029             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/03/2020   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| N/0026              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/01/2020   | 23/04/2020 | PL                               |                                                                                                                                                                                                                                                                         |
| PSUSA/10426         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 03/10/2019   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| /201903             | isavuconazole                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0024/G           | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                        | 26/09/2019 | 23/04/2020 | SmPC, Labelling and PL |                                   |
| IA/0023/G           | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.c.1.a - Change in immediate packaging of the AS | 07/08/2019 | n/a        |                        |                                   |
| PSUSA/10426 /201809 | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                                                            | 11/04/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0021/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                    | 04/04/2019 | 23/04/2020 | Annex II and PL        |                                   |

<div style=\"page-break-after: always\"></div>

|           | Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                  |            |            |                        | B.II.b.1.a -       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------|
| T/0020    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                           | 08/02/2019 | 11/03/2019 | SmPC, Labelling and PL |                    |
| IAIN/0019 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                    | 06/02/2019 | 11/03/2019 | SmPC, Labelling and PL |                    |
|           | an application for a group of variations. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter | 19/12/2018 | n/a        |                        | IA/0018/G This was |
| N/0017    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                              | 13/12/2018 | 11/03/2019 | PL                     |                    |
| IB/0015   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                | 20/11/2018 | 11/03/2019 | SmPC and PL            |                    |

<div style=\"page-break-after: always\"></div>

| PSUSA/10426 /201803   | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                            | 04/10/2018   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| IB/0013               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                              | 30/08/2018   | 11/03/2019 | SmPC                                |
| IA/0014               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                          | 14/08/2018   | n/a        |                                     |
| IA/0012/G             | This was an application for a group of variations. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter | 18/07/2018   | n/a        |                                     |
| PSUSA/10426 /201709   | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                            | 12/04/2018   | n/a        | PRAC Recommendation - maintenance   |
| IB/0010               | B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test                                                                                                                                                                                                              | 04/04/2018   | n/a        |                                     |
| IB/0009               | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                           | 04/04/2018   | n/a        |                                     |

<div style=\"page-break-after: always\"></div>

| IB/0008             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                         | 04/04/2018   | n/a        |                  |                                                                                                                                                                                                                                           |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10426 /201703 | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                                                                                          | 28/09/2017   | n/a        |                  | PRAC Recommendation - maintenance                                                                                                                                                                                                         |
| N/0006              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                     | 24/08/2017   | 30/01/2018 | Labelling and PL |                                                                                                                                                                                                                                           |
| IA/0005/G           | This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits | 18/07/2017   | n/a        |                  |                                                                                                                                                                                                                                           |
| PSUSA/10426 /201609 | Periodic Safety Update EU Single assessment - isavuconazole                                                                                                                                                                                                                                                                                                                                                          | 06/04/2017   | n/a        |                  | PRAC Recommendation - maintenance                                                                                                                                                                                                         |
| IB/0002             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                       | 13/01/2017   | 30/01/2018 | SmPC             | MAH was requested to submit the summaries of two new studies which are updating the Environmental Risk Assessment Report. The Rapporteur conclusions state that Cresemba may pose a risk for the aquatic environment therefore updates to |

<div style=\"page-break-after: always\"></div>

|                     |                                                             |            |     | sections 5.3 and 6.6 of the current SmPC are recommended.   |
|---------------------|-------------------------------------------------------------|------------|-----|-------------------------------------------------------------|
| PSUSA/10426 /201603 | Periodic Safety Update EU Single assessment - isavuconazole | 29/09/2016 | n/a | PRAC Recommendation - maintenance                           |